Arabesque Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Arabesque Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,652	Closed	-$291K	–	144
2022 Q2	$291K	Buy	+3,652	New	+$346K	0.15%	112
2020 Q3	–	Sell	-3,847	Closed	-$214K	–	107
2020 Q2	$214K	Buy	+3,847	New	+$165K	0.14%	78

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Arabesque Asset Management's HZNP Position: Q3 2022 in Review

Arabesque Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 3,652 shares — an estimated $291K sold.

Arabesque Asset Management first reported a position in HZNP in Q2 2020 and held it in 2 quarters. The position peaked at $291K in Q2 2022. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Arabesque Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Arabesque Asset Management sold 3,652 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $291K.
Arabesque Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 2 quarters.
Arabesque Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $291K in Q2 2022.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Arabesque Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.